Malignant thymoma

Current status and future directions

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Malignant thymomas are rare indolent tumours of the anterior superior mediastinum. Despite a benign histologic appearance, some thymomas invade nearby structures or metastasize. Patients are commonly asymptomatic, but same may present with unusual paraneoplastic syndromes such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia. Since tumour biopsy may potentially disrupt the thymic capsule, it is often not performed. Patients are therefore diagnosed and staged at the time of definitive surgery. Thymomas can generally be categorized into two stages: non-invasive and invasive. Prognosis closely parallels the disease stage. Surgery is the principal treatment and is curative in early stage disease. Radiation therapy, either alone or in combination with chemotherapy, is an option for both incompletely or completely resected disease. Chemotherapy is offered to patients with locally advanced, recurrent, or metastatic thymoma, with excellent responses and prolonged survival. Multicentre co-operative group clinical trials are required to assess novel thymoma therapies to maximize patient resources in this uncommon tumour: (C) 2000 Harcourt Publishers Ltd.

Original languageEnglish (US)
Pages (from-to)127-131
Number of pages5
JournalCancer Treatment Reviews
Volume26
Issue number2
DOIs
StatePublished - Apr 2000

Fingerprint

Thymoma
Pure Red-Cell Aplasia
Paraneoplastic Syndromes
Agammaglobulinemia
Neoplasms
Myasthenia Gravis
Mediastinum
Combination Drug Therapy
Capsules
Radiotherapy
Direction compound
Clinical Trials
Biopsy
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Malignant thymoma : Current status and future directions. / Lara, Primo N.

In: Cancer Treatment Reviews, Vol. 26, No. 2, 04.2000, p. 127-131.

Research output: Contribution to journalArticle

@article{5a1ca6e416c342af999afbbd61c8496d,
title = "Malignant thymoma: Current status and future directions",
abstract = "Malignant thymomas are rare indolent tumours of the anterior superior mediastinum. Despite a benign histologic appearance, some thymomas invade nearby structures or metastasize. Patients are commonly asymptomatic, but same may present with unusual paraneoplastic syndromes such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia. Since tumour biopsy may potentially disrupt the thymic capsule, it is often not performed. Patients are therefore diagnosed and staged at the time of definitive surgery. Thymomas can generally be categorized into two stages: non-invasive and invasive. Prognosis closely parallels the disease stage. Surgery is the principal treatment and is curative in early stage disease. Radiation therapy, either alone or in combination with chemotherapy, is an option for both incompletely or completely resected disease. Chemotherapy is offered to patients with locally advanced, recurrent, or metastatic thymoma, with excellent responses and prolonged survival. Multicentre co-operative group clinical trials are required to assess novel thymoma therapies to maximize patient resources in this uncommon tumour: (C) 2000 Harcourt Publishers Ltd.",
author = "Lara, {Primo N}",
year = "2000",
month = "4",
doi = "10.1053/ctrv.1999.0159",
language = "English (US)",
volume = "26",
pages = "127--131",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Malignant thymoma

T2 - Current status and future directions

AU - Lara, Primo N

PY - 2000/4

Y1 - 2000/4

N2 - Malignant thymomas are rare indolent tumours of the anterior superior mediastinum. Despite a benign histologic appearance, some thymomas invade nearby structures or metastasize. Patients are commonly asymptomatic, but same may present with unusual paraneoplastic syndromes such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia. Since tumour biopsy may potentially disrupt the thymic capsule, it is often not performed. Patients are therefore diagnosed and staged at the time of definitive surgery. Thymomas can generally be categorized into two stages: non-invasive and invasive. Prognosis closely parallels the disease stage. Surgery is the principal treatment and is curative in early stage disease. Radiation therapy, either alone or in combination with chemotherapy, is an option for both incompletely or completely resected disease. Chemotherapy is offered to patients with locally advanced, recurrent, or metastatic thymoma, with excellent responses and prolonged survival. Multicentre co-operative group clinical trials are required to assess novel thymoma therapies to maximize patient resources in this uncommon tumour: (C) 2000 Harcourt Publishers Ltd.

AB - Malignant thymomas are rare indolent tumours of the anterior superior mediastinum. Despite a benign histologic appearance, some thymomas invade nearby structures or metastasize. Patients are commonly asymptomatic, but same may present with unusual paraneoplastic syndromes such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia. Since tumour biopsy may potentially disrupt the thymic capsule, it is often not performed. Patients are therefore diagnosed and staged at the time of definitive surgery. Thymomas can generally be categorized into two stages: non-invasive and invasive. Prognosis closely parallels the disease stage. Surgery is the principal treatment and is curative in early stage disease. Radiation therapy, either alone or in combination with chemotherapy, is an option for both incompletely or completely resected disease. Chemotherapy is offered to patients with locally advanced, recurrent, or metastatic thymoma, with excellent responses and prolonged survival. Multicentre co-operative group clinical trials are required to assess novel thymoma therapies to maximize patient resources in this uncommon tumour: (C) 2000 Harcourt Publishers Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0342424736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342424736&partnerID=8YFLogxK

U2 - 10.1053/ctrv.1999.0159

DO - 10.1053/ctrv.1999.0159

M3 - Article

VL - 26

SP - 127

EP - 131

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -